Ace Therapeutics is an expert in the field of liver disease drug development. With extensive research experience, our scientists are keen to identify potential targets for different liver disease drug development, providing research ideas and powerful assistance to liver disease drug development investigators.
Introduction to the Immune Response in Liver Disease
Immune response plays a double-edged role in liver disease. While it can initially help clear pathogens and damaged cells, chronic inflammation driven by a dysregulated immune response contributes significantly to disease progression. Activated immune cells release pro-inflammatory cytokines that perpetuate liver injury and stimulate hepatic stellate cell activation, leading to fibrosis. Modulating the immune response is therefore a crucial consideration in treating chronic liver diseases.
Figure 1. Immune cell signaling and outcomes in the progression of NASH. (Yahoo N., et al. 2023)
What Can We Do?
Based on our professional technical team and advanced technology platform, we aim to provide the most professional services in developing liver disease drugs targeting immune responses.
- Drug Development Targeting Immune Response in the Gut for Liver Disease
The intestine is the largest immune organ of the organism. Therefore, we offer targeted services for the different roles of the intestine in liver disease.
- We will screen for antibiotics that effectively modulate intestinal flora for liver disease treatment based on microbiomics technology.
We will screen for effective modulators that target changes in inflammatory factors caused by abnormal intestinal immunity to directly modulate the immune response in the gut.
For metabolites from the intestine, we will use combined microbiome and metabolome analysis to screen for metabolites with potential for the treatment of liver disease and to fully evaluate their drug-forming properties.
- We will provide drug development services targeting intestinal mucosal immunity for liver disease based on in vitro models of the intestinal mucosa, including but not limited to
For the innate immune response, we will screen drug candidates for restoring intestinal barrier function, inhibiting pattern recognition receptors, stimulating activation of peroxisome proliferators, and other activities to treat liver disease.
For the adaptive immune response, we will screen drug candidates with activities such as modulation of immune cell activity and intestinal humoral response to modulate the intestinal immune response for the treatment of liver disease.
- In view of the important role of intestinal lymphocyte migration in regulating the immune process, we have developed comprehensive drug development service systems for intestinal lymphocyte migration.
First, we will screen for integrins and chemokines that target lymphocyte migration with therapeutic potential for liver disease. Then against these integrins and chemokines, we will screen for active inhibitors by high-throughput techniques, while designing targeted monoclonal antibodies to treat liver disease based on our antibody generation platform.
- Drug Development Targeting Immune Response in the Liver for Liver Disease
The hepatic immune response naturally has an important impact on the development of liver disease. For hepatic immune response, we offer drug development services from both innate and adaptive immune response perspectives as well.
- We will perform an extensive screen for the role of classical immune signaling pathways in liver disease to identify differential proteins. For differential proteins, we will perform high-throughput screening of drugs with potential liver disease therapeutic effects based on appropriate cellular models of liver disease using reporter gene analysis, second messenger assays, and high-intensity imaging.
- We will use genomic and proteomic techniques to analyze and identify immune checkpoint molecules that play a role in liver cancer, and then screen for immune checkpoint inhibitors based on compound libraries.
In addition, based on our many years of research in the field of liver disease, we can provide different models for liver disease studies for the identification of drug candidate activity and mechanistic studies in the drug development process.
With extensive hands-on experience in liver disease drug development, Ace Therapeutics aims to discover every potential therapeutic target for liver disease. Our aim is to facilitate the development of liver disease drugs through multi-target research. If you would like to learn more about our services, please feel free to contact us.
Reference
- Yahoo N., et al. Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation. J Hepatol. 2023, 79(2):538-551.
Related Services
Our products and services are for research use only and can not be used for diagnostic or other purposes.
